New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dibasic potassium phosphate 54 mg/ml; monobasic potassium phosphate 183 mg/ml - solution for injection - active: dibasic potassium phosphate 54 mg/ml monobasic potassium phosphate 183 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dibasic potassium phosphate, quantity: 183 mg/ml; monobasic potassium phosphate, quantity: 54 mg/ml - injection, concentrated - excipient ingredients: water for injections - indications as at 24 march 2004: treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible. the cause of hypophosphataemia should be identified and treated.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphate, monobasic 224 mg in 1 ml - potassium phosphates injection, usp is indicated as a source of phosphate, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte of nutrient solutions. potassium phosphates is contraindicated in diseases where high potassium, high phosphate or low calcium levels may be encountered.

United States - English - NLM (National Library of Medicine)

hospira, inc. - monobasic potassium phosphate (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), dibasic potassium phosphate (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152) - potassium phosphate, monobasic 224 mg in 1 ml - potassium phosphates injection, usp, 3 mm p/ml is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. the concomitant amount of potassium (k+ 4.4 meq/ml) must be calculated into total electrolyte dose of such prepared solutions.     safety has not been established for parenteral nutrition in pediatric patients due to the risk of aluminum toxicity. (see warnings) potassium phosphate is contraindicated in diseases where high potassium, high phosphorus or low calcium levels may be encountered.

United States - English - NLM (National Library of Medicine)

novel laboratories, inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - sodium phosphate, monobasic, monohydrate 1.105 g - monobasic sodium phosphate and dibasic sodium phosphate tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in patients with biopsy-proven acute phosphate nephropathy. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. laxatives and purgatives (including monobasic sodium phosphate and dibasic sodium phosphate tablets) have the potential for abuse by bulimia nervosa patients who frequently have binge eating and vomiting.

Canada - English - Health Canada

fresenius kabi canada ltd - potassium phosphate monobasic; potassium phosphate dibasic - solution - 224mg; 236mg - potassium phosphate monobasic 224mg; potassium phosphate dibasic 236mg - replacement preparations

United States - English - NLM (National Library of Medicine)

hospira, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphate, monobasic 224 mg in 1 ml

United States - English - NLM (National Library of Medicine)

cmp pharma, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral replacement is not possible, insufficient or contraindicated. potassium phosphates injection is indicated as a source of phosphorus for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or contraindicated. limitations of use safety has not been established for parenteral nutrition in adults weighing less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due to the risk of aluminum toxicity [see warnings and precautions (5.5), use in specific population (8.4) ]. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warnings and precautions (5.3) ] - hyperphosphatemia [see warnings and precautions (5.4) ] -

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. - for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warning and precautions (5.3)] - severe renal impairment (egfr less than 30 ml/min/1.73m2 ) or end stage renal disease [see warning and precautions (5.3)] - hyperphosphatemia [see warning and precautions (5.4)] - hypercalcemia or significant hypocalcemia [see warning and precautions (5.4)] risk summary administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with potassium phosphates inj

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals private limited - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. - for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warning and precautions (5.3)]. - hyperphosphatemia [see warning and precautions (5.4)]. - hypercalcemia or significant hypocalcemia [see warning and precautions (5.4)] .  - severe renal impairment (egfr less than 30 ml/min/1.73 m2 ) or end stage renal disease [see warning and precautions (5.3)] . risk summary administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with potassium phosphates injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk phosphorus is an essential mineral element. parenteral supplementation with potassium phosphates should be considered if a pregnant woman’s requirements cannot be fulfilled by oral or enteral intake. risk summary phosphorus and potassium are present in human milk. administration of the recommended dose of potassium phosphates injection is not expected to cause harm to a breastfed infant. there is no information on the effects of potassium phosphates on milk production. the development and health benefits of breastfeeding should be considered along with the mother’s clinical need for potassium phosphates injection and any potential adverse effects on the breastfed child from potassium phosphates injection or from underlying maternal condition. safety and effectiveness of potassium phosphates injection have been established in pediatric patients as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated. - for parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated. because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity [see warnings and precautions (5.6)] . in general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. it may be useful to monitor renal function during treatment [see use in specific populations (8.6)] . potassium and phosphorus are known to be substantially excreted by the kidney and the risk of adverse reactions to potassium phosphates injection may be greater in patients with impaired renal function [see warnings and precautions (5.3, 5.4, 5.5)] . potassium phosphates injection is contraindicated due to the risk of hyperkalemia in patients with severe renal impairment (egfr less than 30 ml/min/1.73 m2 ) or end stage renal disease [see contraindications (4)] . in patients with moderate renal impairment (egfr ≥ 30 ml/min/1.73 m2 to < 60 ml/min/1.73 m2 ), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium and magnesium concentrations [see dosage and administration (2.2, 2.4)].